Emilie Chatelier1, Rafaël Mahieu2, Jean-François Hamel3, Rachel Chenouard4, Pierre Lozac'h1, Agnès Sallé5, Achille Kouatchet6, Ludovic Martin7, Christian Lavigne1, Hélène Pailhoriès4, Geoffrey Urbanski8. 1. Department of Internal Medicine, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. 2. Department of Infectious Diseases, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. 3. Department of Biostatistics, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. 4. Laboratory of Bacteriology, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. 5. Department of Endocrinology, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. 6. Intensive Care Unit, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. 7. Department of Dermatology, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. 8. Department of Internal Medicine, Angers University Hospital, 4, rue Larrey, 49933 Angers, France. Electronic address: urbanskigeoffrey@gmail.com.
Abstract
OBJECTIVES: Pasteurella bacteraemia is rare, but has been associated with a high mortality rate. The aim of this study was to estimate the impact of comorbidities on patients with Pasteurella bacteraemia. METHODS: All cases of Pasteurella bacteraemia in adults treated in our centre between January 2008 and December 2017 were included retrospectively and compared with cases identified in a systematic review of the literature via MEDLINE covering the years 1951-2017. The epidemiological, bacteriological, and clinical data were collected, as well as the instances of death after 30 days. RESULTS: Twenty cases of Pasteurella bacteraemia identified in our centre and 99 cases from the literature review were included. A major comorbidity was found in 80/119 (67.2%) patients. The death rate at 30 days was 31.1%. The most common comorbidities were cirrhosis, immunosuppressive therapy, and malignant diseases. Age was not associated with mortality. On multivariate analysis, the only factor associated with mortality was a major comorbidity (odds ratio 2.78, 95% confidence interval 1.01-7.70; p = 0.04). CONCLUSIONS: This study confirms the high mortality rate and highlights the importance of the host background, independent of age, in Pasteurella bacteraemia. Clinicians should be aware of the comorbidities in cases of Pasteurella infection, due to the poor prognosis of bacteraemia.
OBJECTIVES:Pasteurella bacteraemia is rare, but has been associated with a high mortality rate. The aim of this study was to estimate the impact of comorbidities on patients with Pasteurella bacteraemia. METHODS: All cases of Pasteurella bacteraemia in adults treated in our centre between January 2008 and December 2017 were included retrospectively and compared with cases identified in a systematic review of the literature via MEDLINE covering the years 1951-2017. The epidemiological, bacteriological, and clinical data were collected, as well as the instances of death after 30 days. RESULTS: Twenty cases of Pasteurella bacteraemia identified in our centre and 99 cases from the literature review were included. A major comorbidity was found in 80/119 (67.2%) patients. The death rate at 30 days was 31.1%. The most common comorbidities were cirrhosis, immunosuppressive therapy, and malignant diseases. Age was not associated with mortality. On multivariate analysis, the only factor associated with mortality was a major comorbidity (odds ratio 2.78, 95% confidence interval 1.01-7.70; p = 0.04). CONCLUSIONS: This study confirms the high mortality rate and highlights the importance of the host background, independent of age, in Pasteurella bacteraemia. Clinicians should be aware of the comorbidities in cases of Pasteurella infection, due to the poor prognosis of bacteraemia.
Authors: Kevin B Laupland; Adam G Stewart; Felicity Edwards; Patrick Harris; Claire Heney; Narelle George; Sonali Coulter; David L Paterson Journal: Eur J Clin Microbiol Infect Dis Date: 2022-02-01 Impact factor: 3.267